Acute leukaemia, Acute myeloid leukaemia (AML), Blood cancers, Leukaemia, Myelodysplastic syndrome (MDS)
Results
Phase 2
This trial was looking at reduced intensity stem cell transplants using thymoglobulin. It was for people who had poor risk myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML).
If you can't have full stem cell transplant, you may have a mini transplant. The chemotherapy is less intensive, so they are sometimes called reduced intensity transplants.
Recruitment start: 19 June 2007
Recruitment end: 26 May 2011
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Ghulam J Mufti
Experimental Cancer Medicine Centre (ECMC)
Genzyme Therapeutics
Kings College Hospital NHS Foundation Trust
Last reviewed: 26 November 2013
CRUK internal database number: 2682